PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

imiquimod Side Effects

The reactions most often reported to the FDA for imiquimod (also sold as Aldara), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

2,179
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of imiquimod come from 2,179 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 2,179 reports to the FDA Adverse Event Reporting System (FAERS) for imiquimod (Aldara): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

2,179

Reports Mentioning Death

65

3.0% of reports — not proof the medicine caused the death

Hospitalizations

302

13.9% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

ERYTHEMA
176
FATIGUE
171
PAIN
132
NAUSEA
109
INFLUENZA LIKE ILLNESS
101
APPLICATION SITE ERYTHEMA
94
HEADACHE
93
PYREXIA
83
PRURITUS
80
DIARRHOEA
72
SCAB
72
MALAISE
70
APPLICATION SITE PAIN
67
DIZZINESS
66
ASTHENIA
65
CHILLS
60
RASH
58

Who Reports Side Effects

Gender Distribution

Female 844 (50%)
Male 842 (50%)
Unknown 7

Age Distribution

0-17 59 (5%)
18-44 152 (12%)
45-64 376 (30%)
65-74 309 (24%)
75+ 374 (29%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 65 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 27
PNEUMONIA 7
PLEURAL EFFUSION 5
HERPES SIMPLEX 4
SEPSIS 4
ATRIAL FIBRILLATION 3
CARDIAC ARREST 3
DEHYDRATION 3
DISEASE PROGRESSION 3
DYSPNOEA 3
FALL 3
GENERAL PHYSICAL HEALTH DETERIORATION 3
MALAISE 3
PULMONARY EMBOLISM 3
RESPIRATORY DISTRESS 3
RESPIRATORY FAILURE 3
SCAB 3
ANAEMIA 2
ANXIETY 2

Reactions in Hospitalization Reports

Top reactions in 302 reports where hospitalization was an outcome.

Reaction Reports
ASTHENIA 30
PNEUMONIA 26
DYSPNOEA 21
ERYTHEMA 21
ACUTE KIDNEY INJURY 19
PYREXIA 19
RENAL FAILURE 19
FATIGUE 18
INFLUENZA LIKE ILLNESS 18
CHILLS 17
DECREASED APPETITE 17
DIZZINESS 17
CHRONIC KIDNEY DISEASE 16
HYPONATRAEMIA 16
HYPOTENSION 16
NAUSEA 16
HEADACHE 14
MALAISE 14
BACK PAIN 13

Compare imiquimod vs adapalene →

What the FAERS Data Reveals About imiquimod Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 2,179 voluntary reports linked to imiquimod and its brand equivalents (Aldara), spanning 2004 through 2025. Of those, 65 (3.0%) listed death as an outcome and 302 (13.9%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 50% were female and 50% male; age distribution skews toward 45-64, with 376 reports in that bracket. The single most reported reaction is erythema with 176 submissions, followed by fatigue and pain.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.